Shopping Cart 0
Cart Subtotal
USD 0

NewLink Genetics Corp (NLNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

NewLink Genetics Corp (NewLink) is a clinical stage immuno-oncology company that discovers and develops novel immunotherapeutic products for the treatment of cancer. Its products include small-molecule and biologic immuno-oncology products. NewLink utilizes its HyperAcute cellular immunotherapy technology and IDO pathway inhibitor technology to develop biologic product candidates and small-molecule product candidates, respectively. The company's pipeline products include indoximod and NLG919. It has two HyperAcute Cellular Immunotherapy product candidates in clinical development: tergenpumatucel-L for treatment of advanced lung cancer and dorgenmeltucel-L for melanoma. Algenpantucel-L, Tergenpumatucel-L and Dorgenmeltucel-L. The company also develops and commercializes vaccines for the treatment of infectious diseases using its HyperAcute technology. The company has operations in the US and the UK. NewLink is headquartered in Ames, Iowa, the US.

NewLink Genetics Corp (NLNK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11

Partnerships 13

NewLink Genetics Enters into Agreement with AstraZeneca 13

NewLink Genetics Enters into Agreement with BARDA 14

Licensing Agreements 15

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15

NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16

Merck Enters into Licensing Agreement with NewLink Genetics 17

NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19

NewLink Genetics Enters into Licensing Agreement with Ohio State University 20

Equity Offering 21

NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21

NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22

NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23

NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25

NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To USD 60 Million 26

NewLink Genetics Completes Public Offering Of Shares For USD 52 Million 27

NewLink Genetics Corp-Key Competitors 28

NewLink Genetics Corp-Key Employees 29

NewLink Genetics Corp-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 02, 2018: Newlink Genetics reports third quarter 2018 financial results and announces abstracts to be presented at upcoming medical meetings 31

Jul 31, 2018: NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance 33

May 03, 2018: NewLink Genetics Reports First Quarter 2018 Financial Results 35

Mar 01, 2018: NewLink Genetics Announces Fourth Quarter And Year End 2017 Financial Results 36

Nov 02, 2017: NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program 37

Jul 28, 2017: NewLink Genetics Reports Second Quarter 2017 Financial Results 39

Jul 28, 2017: NewLink Genetics Q2 net loss decreases 40

May 04, 2017: NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance 41

Feb 28, 2017: NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results 42

Corporate Communications 43

May 01, 2018: NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors 43

Mar 21, 2018: NewLink Genetics Appoints Chad A. Johnson to Board of Directors 44

Nov 14, 2017: NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer 45

Product Approvals 46

Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 46

Clinical Trials 47

Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors 47

Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children 48

Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma 49

Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program 50

Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 51

Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics' IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain 52

Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial 53

Jun 02, 2017: Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer 54

May 18, 2017: Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress 55

May 17, 2017: Data from Clinical Study of NewLink Genetics' Indoximod to Be Presented at ASCO 2017 56

May 17, 2017: Data from Clinical Study of NewLink Genetics' Navoximod to Be Presented at ASCO 2017 57

Apr 21, 2017: NewLink Genetics Presents Pipeline Drug Indoximod at ASCO 58

Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 59

Apr 04, 2017: Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary 60

Mar 01, 2017: NewLink Genetics Announces Presentation of Two Abstracts at AACR 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NewLink Genetics Corp, Deals By Therapy Area, 2012 to YTD 2018 9

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11

NewLink Genetics Enters into Agreement with AstraZeneca 13

NewLink Genetics Enters into Agreement with BARDA 14

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15

NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16

Merck Enters into Licensing Agreement with NewLink Genetics 17

NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19

NewLink Genetics Enters into Licensing Agreement with Ohio State University 20

NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21

NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22

NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23

NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25

NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To USD 60 Million 26

NewLink Genetics Completes Public Offering Of Shares For USD 52 Million 27

NewLink Genetics Corp, Key Competitors 28

NewLink Genetics Corp, Key Employees 29

NewLink Genetics Corp, Other Locations 30

NewLink Genetics Corp, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

NewLink Genetics Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

NewLink Genetics Corp (NewLink) is a clinical stage immuno-oncology company that discovers and develops novel immunotherapeutic products for the treatment of cancer. Its products include small-molecule and biologic immuno-oncology products. NewLink utilizes its HyperAcute cellular immunotherapy technology and IDO pathway inhibitor technology to develop biologic product candidates and small-molecule product candidates, respectively. The company's pipeline products include indoximod and NLG919. It has two HyperAcute Cellular Immunotherapy product candidates in clinical development: tergenpumatucel-L for treatment of advanced lung cancer and dorgenmeltucel-L for melanoma. Algenpantucel-L, Tergenpumatucel-L and Dorgenmeltucel-L. The company also develops and commercializes vaccines for the treatment of infectious diseases using its HyperAcute technology. The company has operations in the US and the UK. NewLink is headquartered in Ames, Iowa, the US.

NewLink Genetics Corp (NLNK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11

Partnerships 13

NewLink Genetics Enters into Agreement with AstraZeneca 13

NewLink Genetics Enters into Agreement with BARDA 14

Licensing Agreements 15

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15

NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16

Merck Enters into Licensing Agreement with NewLink Genetics 17

NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19

NewLink Genetics Enters into Licensing Agreement with Ohio State University 20

Equity Offering 21

NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21

NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22

NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23

NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25

NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To USD 60 Million 26

NewLink Genetics Completes Public Offering Of Shares For USD 52 Million 27

NewLink Genetics Corp-Key Competitors 28

NewLink Genetics Corp-Key Employees 29

NewLink Genetics Corp-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 02, 2018: Newlink Genetics reports third quarter 2018 financial results and announces abstracts to be presented at upcoming medical meetings 31

Jul 31, 2018: NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance 33

May 03, 2018: NewLink Genetics Reports First Quarter 2018 Financial Results 35

Mar 01, 2018: NewLink Genetics Announces Fourth Quarter And Year End 2017 Financial Results 36

Nov 02, 2017: NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program 37

Jul 28, 2017: NewLink Genetics Reports Second Quarter 2017 Financial Results 39

Jul 28, 2017: NewLink Genetics Q2 net loss decreases 40

May 04, 2017: NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance 41

Feb 28, 2017: NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results 42

Corporate Communications 43

May 01, 2018: NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors 43

Mar 21, 2018: NewLink Genetics Appoints Chad A. Johnson to Board of Directors 44

Nov 14, 2017: NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer 45

Product Approvals 46

Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 46

Clinical Trials 47

Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors 47

Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children 48

Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma 49

Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program 50

Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 51

Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics' IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain 52

Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial 53

Jun 02, 2017: Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer 54

May 18, 2017: Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress 55

May 17, 2017: Data from Clinical Study of NewLink Genetics' Indoximod to Be Presented at ASCO 2017 56

May 17, 2017: Data from Clinical Study of NewLink Genetics' Navoximod to Be Presented at ASCO 2017 57

Apr 21, 2017: NewLink Genetics Presents Pipeline Drug Indoximod at ASCO 58

Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 59

Apr 04, 2017: Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary 60

Mar 01, 2017: NewLink Genetics Announces Presentation of Two Abstracts at AACR 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NewLink Genetics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NewLink Genetics Corp, Deals By Therapy Area, 2012 to YTD 2018 9

NewLink Genetics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 11

NewLink Genetics Enters into Agreement with AstraZeneca 13

NewLink Genetics Enters into Agreement with BARDA 14

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 15

NewLink Genetics Enters into Licensing Agreement with Augusta University Research Institute 16

Merck Enters into Licensing Agreement with NewLink Genetics 17

NewLink Genetics Enters into Licensing Agreement with Bresagen Xenograft Marketing 19

NewLink Genetics Enters into Licensing Agreement with Ohio State University 20

NewLink Genetics Plans to Raise up to USD250 Million in Public Offering of Securities 21

NewLink Genetics Plans to Raise upto USD60 Million in Public Offering of Shares 22

NewLink Genetics Prices USD51.2 Million in Public Offering of Shares 23

NewLink Genetics Plans to Raise USD40 Million in Public Offering of Shares 25

NewLink Genetics Files Prospectus Public Offering Of Common Stock For Up To USD 60 Million 26

NewLink Genetics Completes Public Offering Of Shares For USD 52 Million 27

NewLink Genetics Corp, Key Competitors 28

NewLink Genetics Corp, Key Employees 29

NewLink Genetics Corp, Other Locations 30

NewLink Genetics Corp, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

NewLink Genetics Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.